Q32 Bio Inc.

NASDAQ:QTTB

Biotechnology

Healthcare
$8.53 -1.70%

-$0.22 today

Market cap
$255.25M
Beta
-0.23
P/E (TTM)
5.4
EPS (TTM)
$2.36
52W Low $1.35High $14.85

Volume 0.26M

Average 0.74M

QTTB Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Q32 Bio Inc.NASDAQ: QTTB

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt rises 33.8% from a year ago

Short-term debt stood at $6.24M at the end of Q1 FY2026, up 33.8% from a year earlier and up 0.1% from the prior quarter. Over 3 fiscal years it compounded at -40.2% a year.

Context

  • Short-term debt amounted to 9.8% of total assets at the end of Q1 FY2026, up 3.9 pp from a year earlier.
  • Short-term debt increased in 2 of the last 3 fiscal years.

What to watch

Whether short-term debt keeps rising in the next quarterly balance sheet after a +33.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.24M+0.1% QoQ
Last fiscal yearDec 2025
$6.93M+123.7% YoY
Year agoMar 2025
$4.66M+33.8% since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.8%——
1 year+123.7%——
3-year CAGR-40.2%——
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
6.93M USD
Year-over-year change
+123.7%
4-year CAGR
+130.4%

Short-term Debt vs competitors

How QTTB compares with its peers on the latest reported figures

  • QTTB's Mar 2026 short-term debt of $6.24M is the highest of the 5 companies compared; the peer median is $320.5K.
  • Its year-over-year change of +33.8% is the highest of 2, against a peer median of -94.2%.
  • Short-term debt amounts to 9.8% of total assets for QTTB, versus a peer median of 0.1%.
QTTB Competitors Peer median
Short-term Debt for QTTB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
QTTBQ32 Bio Inc.Mar 2026$6.24M +33.8%-40.2%9.8%
VRCAVerrica Pharmaceuticals Inc.Mar 2026$744K -94.2%—1.9%
SABSSAB Biotherapeutics, Inc.Jun 2026$641K —+7.2%0.3%
ANTXAN2 Therapeutics, Inc.Mar 2026$0 ——0.0%
BOLDBoundless Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding QTTB) $320.5K-94.2%+7.2%0.1%

Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents108.38M43.89M25.62M77.97M48.3M
Short-term Investments47.49M0000
Net Receivables01.06M755K555K0
Inventory01.75M000
Other Current Assets36.04M146K83K396K6.75M
Total Current Assets191.91M46.85M28.72M81.88M55.05M
Property, Plant & Equipment (Net)17.86M9.17M8.08M7.09M6.08M
Goodwill00000
Intangible Assets00000
Long-term Investments1.95M25.81M5.65M2.6M647K
Tax Assets00000
Other Non-current Assets0(20.06M)10.26M763K0
Total Non-current Assets19.81M14.92M18.34M10.46M6.73M
Total Assets211.72M61.77M47.06M92.33M61.78M
Account Payables2.37M1.44M3.47M2.99M879K
Short-term Debt246K32.4M878K3.1M6.93M
Tax Payables0570K316K00
Deferred Revenue3.21M14.53M000
Other Current Liabilities11.41M2.79M3M5.68M3.54M
Total Current Liabilities17.23M57.87M14.11M16.47M11.35M
Long-term Debt05.07M43.18M9.56M3.47M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.16M11.32M000
Other Non-current Liabilities0111.45M166.45M55M0
Total Non-current Liabilities24.84M134.62M215.87M70.19M8.42M
Total Liabilities42.07M192.49M229.98M86.66M19.76M
Common Stock6K6K1K2K2K
Retained Earnings(424.13M)(429.14M)(187.08M)(234.81M)(204.99M)
Accumulated OCI(7K)(404K)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity169.65M(130.71M)(182.92M)5.68M42.01M
Total Debt23.93M44.73M50.84M18.9M15.34M
Net Debt(84.45M)838K25.22M(59.06M)(32.95M)

Q32 Bio Inc.

NASDAQ:QTTB

Intrinsic Alpha fair value

Locked

Current Price

$8.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.